Search

Grepafloxacin

Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States

Ulobetasol

[L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]

Clobetasol propionate

[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]

Brivaracetam

Briviact received FDA approval on February 19, 2016 [L760].

Donislecel

[L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196] … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.

Raxibacumab

FDA approved on December 14, 2012.

Abacavir

Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring.

Alcloxa

Estradiol dienanthate

effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone … Estradiol is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).

Tesidolumab

Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration